collection
https://read.qxmd.com/read/33495152/autoantibodies-targeting-telomere-associated-proteins-in-systemic-sclerosis
#1
Brittany L Adler, Francesco Boin, Paul J Wolters, Clifton O Bingham, Ami A Shah, Carol Greider, Livia Casciola-Rosen, Antony Rosen
OBJECTIVES: Systemic sclerosis (SSc) is an autoimmune fibrotic disease affecting multiple tissues including the lung. A subset of patients with SSc with lung disease exhibit short telomeres in circulating lymphocytes, but the mechanisms underlying this observation are unclear. METHODS: Sera from the Johns Hopkins and University of California, San Francisco (UCSF) Scleroderma Centers were screened for autoantibodies targeting telomerase and the shelterin proteins using immunoprecipitation and ELISA...
July 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33887471/fast-track-clinic-for-early-diagnosis-of-polymyalgia-rheumatica-impact-on-symptom-duration-and-prednisolone-initiation
#2
Line L Frølund, Christoffer Våben, Mette Dam, Søren G Kjær, Berit D Nielsen, René D Østgård, Kresten K Keller
OBJECTIVES: To evaluate the efficacy of a fast track clinic (FTC) for patients suspected of polymyalgia rheumatica (PMR) regarding symptom duration, prednisolone initiation before rheumatological assessment, number of hospital contacts before diagnosis, and cancer diagnosis. METHODS: It is a retrospective cohort study with a one year follow-up period. Patients referred to the FTC (1st August 2016 to 25th June 2019) were compared to a historical cohort of PMR patients (1st August 2014 to 1st August 2016)...
April 19, 2021: Joint, Bone, Spine: Revue du Rhumatisme
https://read.qxmd.com/read/33571506/clinical-significance-of-interstitial-lung-disease-and-its-acute-exacerbation-in-microscopic-polyangiitis
#3
Hironao Hozumi, Masato Kono, Hirotsugu Hasegawa, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura, Koshi Yokomura, Hidenori Nakamura, Takafumi Suda
BACKGROUND: Presence of interstitial lung disease (ILD) is thought to be associated with mortality in microscopic polyangiitis (MPA); however, evidence on MPA-ILD remains lacking. Acute exacerbation (AE) refers to rapidly progressive, fatal respiratory deterioration that may develop in patients with various ILDs. No study has investigated the clinical significance of AE in MPA-ILD. RESEARCH QUESTION: We aimed to determine the clinical picture and prognostic factors, the incidence of AE, and the risk factors in patients with MPA-ILD...
June 2021: Chest
https://read.qxmd.com/read/32546500/advances-in-the-diagnosis-and-management-of-igg4-related-disease
#4
REVIEW
Marco Lanzillotta, Gaia Mancuso, Emanuel Della-Torre
IgG4 related disease was recognized as a unified disease entity only 15 years ago. Awareness of IgG4 related disease has increased worldwide since then, and specialists are now familiar with most of its clinical manifestations. Involvement of the pancreato-biliary tract, retroperitoneum/aorta, head and neck, and salivary glands are the most frequently observed disease phenotypes, differing in epidemiological features, serological findings, and prognostic outcomes. In view of this multifaceted presentation, IgG4 related disease represents a great mimicker of many neoplastic, inflammatory, and infectious conditions...
June 16, 2020: BMJ: British Medical Journal
https://read.qxmd.com/read/33208345/interleukin-6-receptor-inhibition-in-primary-sj%C3%A3-gren-syndrome-a-multicentre-double-blind-randomised-placebo-controlled-trial
#5
Renaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, Pierre Duffau, David Saadoun, Eric Hachulla, Hatron Pierre Yves, Carine Salliot, Aleth Perdriger, Jacques Morel, Arsène Mékinian, Olivier Vittecoq, Jean-Marie Berthelot, Emanuelle Dernis, Veronique Le Guern, Philippe Dieudé, Claire Larroche, Christophe Richez, Thierry Martin, Charles Zarnitsky, Gilles Blaison, Pierre Kieffer, François Maurier, Azeddine Dellal, Stephanie Rist, Emmanuel Andres, Anne Contis, Emmanuel Chatelus, Christelle Sordet, Jean Sibilia, Cécile Arnold, Mira Y Tawk, Ouafaa Aberkane, Lise Holterbach, Patrice Cacoub, Alain Saraux, Xavier Mariette, Nicolas Meyer, Jacques-Eric Gottenberg
OBJECTIVES: No immunomodulatory drug has been approved for primary Sjögren's syndrome, a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the efficacy of targeting interleukin 6 receptor in patients with Sjögren's syndrome-related systemic complications. METHODS: Multicentre double-blind randomised placebo-controlled trial between 24 July 2013 and 16 July 2018, with a follow-up of 44 weeks, involving 17 referral centres. Inclusion criteria were primary Sjögren's syndrome according to American European Consensus Group criteria and score ≥5 for the EULAR Sjögren's Syndrome Disease activity Index (ESSDAI, score of systemic complications)...
November 18, 2020: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33038062/efficacy-and-safety-of-e6011-an-anti-fractalkine-monoclonal-antibody-in-patients-with-active-rheumatoid-arthritis-with-inadequate-response-to-methotrexate-results-of-a-randomized-double-blind-placebo-controlled-phase-ii-study
#6
RANDOMIZED CONTROLLED TRIAL
Yoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, Toshihiro Nanki, Hisanori Umehara, Nobuyuki Yasuda, Fumitoshi Tago, Yasumi Kitahara, Makoto Kawakubo, Kentaro Torii, Seiichiro Hojo, Tetsu Kawano, Toshio Imai
OBJECTIVE: To evaluate the efficacy and safety of E6011, a humanized IgG2 monoclonal antibody against human fractalkine (FKN), in a phase II, double-blind, placebo-controlled study in rheumatoid arthritis (RA) patients. METHODS: Patients with moderate-to-severe RA who had an inadequate response to methotrexate were randomly assigned to a placebo group or to E6011 100-mg, 200-mg, or 400/200-mg groups at a 2:1:2:2 ratio. During the 24-week period, patients received the study drug subcutaneously at weeks 0, 1, and 2 and then once every 2 weeks...
April 2021: Arthritis & Rheumatology
https://read.qxmd.com/read/33690049/giant-cell-arteritis-related-aortic-dissection-a-multicenter-retrospective-study
#7
Hubert de Boysson, Olivier Espitia, Maxime Samson, Nathalie Tieulié, Claude Bachmeyer, Thomas Moulinet, Anael Dumont, Samuel Deshayes, Bernard Bonnotte, Christian Agard, Achille Aouba
PURPOSE: To describe characteristics and outcomes of patients with giant cell arteritis (GCA)-related aortic dissection. PATIENTS AND METHODS: We retrospectively included, through a nationwide GCA network, all patients who had an aortic dissection either revealing GCA or occurring during follow-up. RESULTS: A total of 46 patients were included in this study. Aortic dissection was inaugural and led to GCA diagnosis in 21 patients, whereas it occurred during follow-up in the 25 others, at a median of 53 [1-265] months after GCA diagnosis...
April 2021: Seminars in Arthritis and Rheumatism
https://read.qxmd.com/read/33851956/long-term-outcomes-and-prognosis-in-new-onset-psoriasis
#8
Axel Svedbom, Lotus Mallbris, Per Larsson, Pernilla Nikamo, Katarina Wolk, Petra Kjellman, Enikö Sonkoly, Liv Eidsmo, Ulla Lindqvist, Mona Ståhle
Importance: Psoriasis is a heterogeneous disease. Improved understanding of prognosis and long-term outcomes in new-onset psoriasis may improve care. Objective: To describe the clinical course of psoriasis and identify possible indicators of long-term outcomes. Design, Setting, and Participants: The Stockholm Psoriasis Cohort was a noninterventional inception cohort study enrolling patients between 2001 and 2005. The present study was conducted from January 15, 2019, to February 5, 2021...
April 14, 2021: JAMA Dermatology
https://read.qxmd.com/read/33760371/mycophenolate-mofetil-versus-cyclophosphamide-for-remission-induction-in-childhood-polyarteritis-nodosa-an-open-label-randomised-bayesian-non-inferiority-trial
#9
Paul A Brogan, Barbara Arch, Helen Hickey, Jordi Anton, Este Iglesias, Eileen Baildam, Kamran Mahmood, Gavin Cleary, Elena Moraitis, Charalampia Papadopoulou, Michael W Beresford, Phil Riley, Selcan Demir, Seza Ozen, Giovanna Culeddu, Dyfrig A Hughes, Pavla Dolezalova, Lisa V Hampson, John Whitehead, David Jayne, Nicola Ruperto, Catrin Tudur-Smith, Despina Eleftheriou
OBJECTIVE: Cyclophosphamide (CYC) is used in clinical practice off-label for induction of remission of childhood polyarteritis nodosa (cPAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative: we explored their relative effectiveness in a randomised controlled trial (RCT). METHODS: International, open-label, Bayesian, RCT investigating the relative effectiveness of MMF and CYC for remission induction in cPAN. Eleven newly-diagnosed patients were randomised (1:1) to MMF or intravenous-CYC; all received the same glucocorticoid regimen...
March 24, 2021: Arthritis & Rheumatology
https://read.qxmd.com/read/33199274/efficacy-and-safety-of-fasinumab-in-patients-with-chronic-low-back-pain-a-phase-ii-iii-randomised-clinical-trial
#10
Paula Dakin, Alan J Kivitz, Joseph S Gimbel, Nebojsa Skrepnik, Stephen J DiMartino, Chetachi A Emeremni, Haitao Gao, Neil Stahl, David M Weinreich, George D Yancopoulos, Gregory P Geba
OBJECTIVES: To study the efficacy and safety of fasinumab in moderate-to-severe, chronic low back pain (CLBP). METHODS: In this phase II/III, double-blind, placebo-controlled study, patients with CLBP aged ≥35 years with inadequate pain relief/intolerance to acetaminophen, non-steroidal anti-inflammatory drugs and opioids were randomised to fasinumab 6 or 9 mg subcutaneous every 4 weeks (Q4W), 9 mg intravenous every 8 weeks (Q8W) or placebo. Primary endpoint was change from baseline to week 16 in average daily low back pain intensity (LBPI) numeric rating score...
November 16, 2020: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33615722/effects-of-dietary-patterns-on-serum-urate-results-from-a-randomized-trial-of-the-effects-of-diet-on-hypertension
#11
Stephen P Juraschek, Chio Yokose, Natalie McCormick, Edgar R Miller, Lawrence J Appel, Hyon K Choi
OBJECTIVE: To determine whether the Dietary Approaches to Stop Hypertension (DASH) diet or an alternative, simplified diet, emphasizing high-fiber fruits and vegetables (the FV diet), lowers serum urate levels. METHODS: We conducted a secondary study of the DASH feeding study, a 3-arm, parallel-design, randomized trial of 459 adults with systolic blood pressure (BP) of <160 mm Hg and diastolic BP of 80-95 mm Hg, who were not receiving BP medications. Participants were randomized to receive 8 weeks of monitored feeding and ate 1 of 3 diets: 1) a typical American diet (control), 2) the FV diet, a diet rich in fruits and vegetables but otherwise similar to the control diet, or 3) the DASH diet, which was rich in fruits, vegetables, and low-fat dairy products, and reduced in fat, saturated fat, and cholesterol...
June 2021: Arthritis & Rheumatology
https://read.qxmd.com/read/33471030/association-of-potent-and-very-potent-topical-corticosteroids-and-the-risk-of-osteoporosis-and-major-osteoporotic-fractures
#12
Alexander Egeberg, Peter Schwarz, Torben Harsløf, Yuki M F Andersen, Anton Pottegård, Jesper Hallas, Jacob P Thyssen
Importance: Systemic and inhaled corticosteroids negatively affect bone remodeling and cause osteoporosis and bone fracture when given continuously or in high doses. However, risk of osteoporosis and major osteoporotic fracture (MOF) after application of topical corticosteroids (TCSs) is largely unexplored. Objective: To examine the association between cumulative exposure to potent and very potent TCSs and risk of osteoporosis and MOF. Design, Setting, and Participants: This nationwide retrospective cohort study included 723 251 Danish adults treated with potent or very potent TCSs from January 1, 2003, to December 31, 2017...
March 1, 2021: JAMA Dermatology
https://read.qxmd.com/read/33504485/filgotinib-versus-placebo-or-adalimumab-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-methotrexate-a-phase-iii-randomised-clinical-trial
#13
Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J Abraham Simon, Herbert S B Baraf, Uma Kumar, Franziska Matzkies, Beatrix Bartok, Lei Ye, Ying Guo, Chantal Tasset, John S Sundy, Angelika Jahreis, Mark C Genovese, Neelufar Mozaffarian, Robert B M Landewé, Sang-Cheol Bae, Edward C Keystone, Peter Nash
OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX). METHODS: This 52-week, multicentre, double-blind, placebo-controlled and active-controlled phase III trial evaluated once-daily oral filgotinib in patients with RA randomised 3:3:2:3 to filgotinib 200 mg (FIL200) or filgotinib 100 mg (FIL100), subcutaneous adalimumab 40 mg biweekly, or placebo (through week 24), all with stable weekly background MTX...
July 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33613571/apremilast-in-refractory-beh%C3%A3-et-s-syndrome-a-multicenter-observational-study
#14
Matheus Vieira, Solène Buffier, Mathieu Vautier, Alexandre Le Joncour, Yvan Jamilloux, Mathieu Gerfaud-Valentin, Laurence Bouillet, Estibaliz Lazaro, Stéphane Barete, Laurent Misery, Delphine Gobert, Tiphaine Goulenok, Olivier Fain, Karim Sacre, Pascal Sève, Patrice Cacoub, Cloé Comarmond, David Saadoun
Objective: Mucocutaneous and joint disorders are the most common manifestations in Behçet's syndrome (BS) and are frequently clustered in the so-called minor forms of BS. There remains a need for safe and effective treatment for joint lesions in BS. We report the long-term safety and effectiveness of apremilast in refractory joint and mucocutaneous manifestations of BS. Methods: French nationwide multicenter study including 50 BS patients with either active joint and/or mucocutaneous manifestations resistant to colchicine and/or DMARDs...
2020: Frontiers in Immunology
https://read.qxmd.com/read/32988845/progressive-interstitial-lung-disease-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-in-the-eustar-database
#15
Anna-Maria Hoffmann-Vold, Yannick Allanore, Margarida Alves, Cathrine Brunborg, Paolo Airó, Lidia P Ananieva, László Czirják, Serena Guiducci, Eric Hachulla, Mengtao Li, Carina Mihai, Gabriela Riemekasten, Petros P Sfikakis, Otylia Kowal-Bielecka, Antonella Riccardi, Oliver Distler
OBJECTIVES: To identify overall disease course, progression patterns and risk factors predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD (SSc-ILD), using data from the European Scleroderma Trials And Research (EUSTAR) database over long-term follow-up. METHODS: Eligible patients with SSc-ILD were registered in the EUSTAR database and had measurements of forced vital capacity (FVC) at baseline and after 12±3 months...
February 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/33587686/safety-and-efficacy-of-checkpoint-inhibition-in-patients-with-melanoma-and-preexisting-autoimmune-disease-a-cohort-study
#16
Monique K van der Kooij, Karijn P M Suijkerbuijk, Maureen J B Aarts, Franchette W P J van den Berkmortel, Christian U Blank, Marye J Boers-Sonderen, Jesper van Breeschoten, Alfonsus J M van den Eertwegh, Jan Willem B de Groot, John B A G Haanen, Geke A P Hospers, Djura Piersma, Rozemarijn S van Rijn, Albert J Ten Tije, Astrid A M van der Veldt, Gerard Vreugdenhil, Michiel C T van Zeijl, Michel W J M Wouters, Olaf M Dekkers, Ellen Kapiteijn
BACKGROUND: Because immune checkpoint inhibition (ICI) can cause immune-related adverse events (irAEs) mimicking immunologic diseases, patients with preexisting autoimmune disease (AID) have been excluded from clinical trials. OBJECTIVE: To evaluate the safety and efficacy of ICI in patients with advanced melanoma with and without AID. DESIGN: Nationwide cohort study. SETTING: The Netherlands. PATIENTS: 4367 patients with advanced melanoma enrolled in the Dutch Melanoma Treatment Registry (DMTR) between July 2013 and July 2018 and followed through February 2019...
May 2021: Annals of Internal Medicine
https://read.qxmd.com/read/33521772/metformin-and-risk-of-mortality-in-patients-hospitalised-with-covid-19-a-retrospective-cohort-analysis
#17
Carolyn T Bramante, Nicholas E Ingraham, Thomas A Murray, Schelomo Marmor, Shane Hovertsen, Jessica Gronski, Chace McNeil, Ruoying Feng, Gabriel Guzman, Nermine Abdelwahab, Samantha King, Leonardo Tamariz, Thomas Meehan, Kathryn M Pendleton, Bradley Benson, Deneen Vojta, Christopher J Tignanelli
Background: Type 2 diabetes and obesity, as states of chronic inflammation, are risk factors for severe COVID-19. Metformin has cytokine-reducing and sex-specific immunomodulatory effects. Our aim was to identify whether metformin reduced COVID-19-related mortality and whether sex-specific interactions exist. Methods: In this retrospective cohort analysis, we assessed de-identified claims data from UnitedHealth Group (UHG)'s Clinical Discovery Claims Database. Patient data were eligible for inclusion if they were aged 18 years or older; had type 2 diabetes or obesity (defined based on claims); at least 6 months of continuous enrolment in 2019; and admission to hospital for COVID-19 confirmed by PCR, manual chart review by UHG, or reported from the hospital to UHG...
January 2021: The Lancet. Healthy longevity
https://read.qxmd.com/read/33158881/points-to-consider-for-the-treatment-of-immune-mediated-inflammatory-diseases-with-janus-kinase-inhibitors-a-consensus-statement
#18
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, Maxime Dougados, Roy M Fleischmann, Klaus Geissler, Iain McInnes, Janet E Pope, Désirée van der Heijde, Michaela Stoffer-Marx, Tsutomu Takeuchi, Michael Trauner, Kevin L Winthrop, Maarten de Wit, Daniel Aletaha, Xenofon Baraliakos, Wolf-Henning Boehncke, Paul Emery, John D Isaacs, Joel Kremer, Eun Bong Lee, Walter P Maksymowych, Marieke Voshaar, Lai-Shan Tam, Yoshiya Tanaka, Filip van den Bosch, René Westhovens, Ricardo Xavier, Josef S Smolen
OBJECTIVES: Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety. METHODS: Existing data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi...
January 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/32856066/renal-involvement-in-eosinophilic-granulomatosis-with-polyangiitis-egpa-a-multicentric-retrospective-study-of-63-biopsy-proven-cases
#19
Cécile-Audrey Durel, Renato A Sinico, Vitor Teixeira, David Jayne, Xavier Belenfant, Sylvain Marchand-Adam, Gregory Pugnet, Jacques Gaultier, Thomas Le Gallou, Dimitri Titeca-Beauport, Christian Agard, Christelle Barbet, Antoine Bardy, Daniel Blockmans, Jean-Jacques Boffa, Julien Bouet, Vincent Cottin, Yoann Crabol, Christophe Deligny, Marie Essig, Pascal Godmer, Philippe Guilpain, Sandrine Hirschi-Santelmo, Cédric Rafat, Xavier Puéchal, Camille Taillé, Alexandre Karras
OBJECTIVE: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic small-vessel vasculitis characterized by asthma, hypereosinophilia and ANCA positivity in 40% of patients. Renal involvement is rare and poorly described, leading to this renal biopsy-proven based study in a large EGPA cohort. METHODS: We conducted a retrospective multicentre study including patients fulfilling the 1990 ACR criteria and/or the 2012 revised Chapel Hill Consensus Conference criteria for EGPA and/or the modified criteria of the MIRRA trial, with biopsy-proven nephropathy...
August 28, 2020: Rheumatology
https://read.qxmd.com/read/26106209/chronic-periaortitis-with-thoracic-aorta-and-epiaortic-artery-involvement-a-systemic-large-vessel-vasculitis
#20
COMPARATIVE STUDY
Alessandra Palmisano, Maria L Urban, Domenico Corradi, Rocco Cobelli, Federico Alberici, Federica Maritati, Annibale Versari, Nicolò Pipitone, Carlo Salvarani, Carlo Buzio, Augusto Vaglio
OBJECTIVE: Chronic periaortitis (CP) is a rare disease characterized by fibro-inflammatory tissue surrounding the abdominal aorta and the iliac arteries. Anecdotal reports have shown that CP may also involve other vascular districts, particularly the thoracic aorta. The aim of this study was to investigate the thoracic aorta and epiaortic artery involvement in CP. METHODS: Patients were eligible if they had undergone imaging studies assessing inflammatory involvement of the thoracic aorta and its major branches (e...
November 2015: Rheumatology
label_collection
label_collection
16352
1
2
2020-12-22 07:30:48
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"